Reunion Neuroscience Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Reunion Neuroscience Inc (REUN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Reunion Neuroscience Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 20M vs 84M combined for tracked competitors (19.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-80.6%) for its tracked peer group.
- Profitability: Its -186.9% net margin compares with -7,735.4% for the peer group.
- Peer revenue share: Reunion Neuroscience Inc accounted for 83.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.90M compares with $0.13M for the peer group (6.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
REUN Sales vs. its Competitors, Q4 2023
With a net margin of -186.94 %, Reunion Neuroscience Inc achieved higher profitability than its competitors (-7,735.43 %).
Reunion Neuroscience Inc generated 83.03 % of the combined sales of its peer group.
Reunion Neuroscience Inc vs. its Competitors, Q4 2023
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Reunion Neuroscience Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Reunion Neuroscience Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Reunion Neuroscience Inc's competitor groups requires a Commercial License.
Reunion Neuroscience Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Reunion Neuroscience Inc | - | - | - | - |
| Competitors combined (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
REUN Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 2 | Compass Pathways Plc | 282.9% | Outperformed |
| 3 | Sage Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Reunion Neuroscience Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Reunion Neuroscience Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Reunion Neuroscience Inc | 13.04 | 19.87 |
| Karuna Therapeutics Inc | 12,190.19 | 11.29 |
| Definium Therapeutics Inc | 4,212.66 | - |
| Compass Pathways Plc | 1,679.90 | - |
| Sage Therapeutics Inc | 543.46 | 70.41 |
| Akili Inc | 33.92 | 1.95 |
| SUBTOTAL | 18,673.16 | 103.52 |
Sources: Reunion Neuroscience Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Reunion Neuroscience Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Reunion Neuroscience Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Reunion Neuroscience Inc | 13 | 903,199 | -1,667,704 |
| Karuna Therapeutics Inc | 12,190 | 1,129,100 | -43,368,000 |
| Definium Therapeutics Inc | 4,213 | - | - |
| Compass Pathways Plc | 1,680 | - | -2,526,840 |
| Sage Therapeutics Inc | 543 | 199,462 | -853,244 |
| Akili Inc | 34 | 17,088 | -425,833 |
| PEERS TOTAL | 18,660 | 132,147 | -2,419,261 |
Reunion Neuroscience Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-80.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Reunion Neuroscience Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Reunion Neuroscience Inc | 3.22 | 3.52 | - |
| Karuna Therapeutics Inc | 6.61 | 31.17 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Compass Pathways Plc | 1.28 | 1.47 | 0.48 |
| Sage Therapeutics Inc | 1.30 | 8.83 | - |
| Akili Inc | 5.33 | 6.80 | 0.18 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Reunion Neuroscience Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Reunion Neuroscience Inc | Q1 2023 | +412.4 % | - |
| Karuna Therapeutics Inc | Q3 2023 | - | - |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | +265.8 % | - |
| Akili Inc | Q1 2024 | +238.9 % | - |
| PEERS TOTAL | +189.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Reunion Neuroscience Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Reunion Neuroscience Inc | Q1 2023 | - | - |
| Karuna Therapeutics Inc | Q3 2023 | - | +175.5 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | - | - |
| Akili Inc | Q1 2024 | +26.3 % | +7,566.7 % |
Reunion Neuroscience Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Reunion Neuroscience Inc | - | - | - |
| Karuna Therapeutics Inc | - | - | - |
| Definium Therapeutics Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
| Sage Therapeutics Inc | - | - | - |
| Akili Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Reunion Neuroscience Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Reunion Neuroscience Inc | - | 0.66 |
| Karuna Therapeutics Inc | - | 1,079.64 |
| Definium Therapeutics Inc | - | - |
| Compass Pathways Plc | - | - |
| Sage Therapeutics Inc | - | 7.72 |
| Akili Inc | - | 17.41 |
| PEERS AVERAGE | - | 180.38 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.